Archive
1250 articles, sorted by publication time.
After expanding the U.S. indication to include all serotypes of generalized myasthenia gravis in adults, argenx will next use trials in myositis and multifocal motor neuropathy to test whether its immunology portfolio can evolve from a single blockbuster into a multi-disease, multi-target combination.
Definium’s orally disintegrating lysergide formulation significantly reduced generalized anxiety symptoms with a single 100-microgram dose in a 214-person trial; the results add late-stage evidence for psychedelic drug therapy, but full safety data, the reliability of blinding, and long-term effects remain to be disclosed.
mRNA-1469 will be evaluated in healthy adults for safety, tolerability, and immune response for the first time; the trial does not mean the vaccine has been approved for market, but it is a critical starting point for closing the preparedness gap against Bundibugyo ebolavirus.
A 20-patient randomized trial will assess the safety of ELI-002 7P in combination with mFOLFIRINOX in resectable or borderline resectable pancreatic cancer, while asking whether adding tislelizumab can further stimulate antitumor immunity.
A mouse study shows that short-term alteration of the gut microbiome can reduce the liver’s interception of nanoparticle chemotherapy drugs, prolong their circulation in the blood, and increase tumor accumulation. This “microbiome–bile acid–liver macrophage” pathway offers a new direction for regulating drug delivery.
In 113 participants, SANDI diffusion MRI distinguished striatal signals consistent with neuronal loss and linked brain atrophy with motor performance; however, it remains an indirect estimate, and longitudinal and cross-scanner validation is still needed before it can become a clinical trial biomarker.
Researchers recreated the cellular and matrix features of heart valves in a culture dish and modeled disease-related inflammatory responses; its immediate value lies in studying pathology and testing drugs, while living replacement valves that can grow with children remain a long-term goal.
The research team combined tumor data from the I-SPY2 clinical trial with 44 breast cancer organoids, reproducing some treatment responses and searching for combinations that could overcome drug resistance; the findings remain a preprint supported by laboratory validation, and their use in selecting drugs for individual patients is still some way off.
A research team tracked the journey of a KRAS antisense oligonucleotide inside pancreatic cancer cells and found that CD44, EPHA2, and endosomal repair mechanisms jointly determine whether the drug can reach its target; the findings remain at the preclinical stage and have not yet undergone peer review.
The FDA has cleared ThinkSono’s real-time guidance software, enabling personnel without specialized ultrasound training to acquire lower-extremity venous images for interpretation by remote clinical personnel; a multicenter study supports its feasibility while leaving questions about imaging failures and real-world benefits.
Using Down syndrome as a proof of concept, a research team converted DNA methylation signatures from postnatal blood into a cross-tissue classifier, with the aim of adding another layer of evidence for interpreting variants of uncertain significance identified by prenatal sequencing; however, hurdles including expansion to other diseases and prospective validation remain before it can become a routine clinical test.
SKB565 is designed to carry a toxin and an immunomodulator within the same antibody-drug conjugate, enabling tumor killing and immune activation to occur simultaneously. Chinese regulators have cleared its clinical trial application, but its efficacy and safety in humans and key design details remain undisclosed.